Programska knjižnica 9. Lošinjskih dana bioetike - Hrvatsko ...

PROSTITUTION AND AMORALITY
Prostitution has always been considered “the oldest profession in the
world”. Social factors have mostly been accused for its appearance and
perpetuation. Behind that phrase hides, on the one hand, a falsely fatalistic
generosity, and on the other hand, an aristocratic scorn. Such a notion was
used by those who wished to avoid responsibility, rethinking and guilt.
Guided by the view that the nature of a “phenomenon” can not be perceived
without the knowledge of the nature of an individual who makes
the phenomenon, we started the investigation by examining the character
features of women involved in prostitution.
In this presentation, we will define prostitution through the prism of
morals, and emphasize our stance against the legalization of same.
ZORAN TODOROVIĆ, MILICA PROSTRAN
School of Medicine, University of Belgrade, Serbia /
Medicinski fakultet, Univerzitet u Beogradu, Srbija
BIOETHICAL CHALLENGES
IN BIOPHARMACEUTICAL DRUG DEVELOPMENT
Unlike conventional, small molecular weight drugs, biopharmaceuticals
are proteins with complex three dimensional structures obtained with
the help of DNA technology and hybridoma techniques. Immunogenicity of
biopharmaceuticals should always be tested in clinical settings due to low
predictive value of preclinical animal models. However, non-human primates
(NHP) and transgenic mice could be used to address certain aspects
of immunogenicity. Substantial efforts have been made to reduce NHP use
in biopharmaceutical drug development, e.g. study design improvements
and changes in regulatory policy. In addition, several expert groups are active
in this field (e.g. NC3Rs, BioSafe, and Biopharmaceutical Technical
Group). Despite that, there is an increasing trend of use of NHP in preclinical
safety testing of biopharmaceuticals, especially regarding monoclonal
antibodies. Other potential bioethical issues related to biopharmaceutical
drug development are their cost/effectiveness ratio, clinical safety assessment
and production of biosimilars.
127